Novartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely expensive spinal muscular atrophy gene therapy Zolgensma.
The FDA has approved emergency use of malaria drugs championed by president Donald Trump for use in patients hospitalised with COVID-19, after warning against the potentially lethal consequ
Novartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting disease spinal muscular atrophy – information that will be closely
